About the report
Using data derived from Beacon as of 24th of July 2023, the following report provides analysis of the existing DDR landscape, an overview of what has happened so far in 2023, and a look at what the future might bring.
The analysis includes:
- H1 Highlights and Future of DDR – An overview of H1 highlights including key announcements, conferences and a detailed analysis of the standout target of the year – ATR aswell as a look towards the future of DDR
- The Drug and Trial Landscape – Analysis of the drug and trial landscape by disease indication, target, therapeutic class and more
How the most complete DDR database can help you
What we cover
Beacon DNA Damage Response (DDR) covers trial and drug records for clinical, preclinical, approved and discontinued therapeutics targeting key points in DNA damage response pathways.
This module identifies drugs utilizing the concept of synthetic lethality, and covers DDR repair pathway components, including:
- Damage Sensors
- Signalling/Mediator Proteins
- Effector Proteins
- Cell Cycle Checkpoints
- DNA Metabolism when in relation to repair and recombination
Several key therapeutic targets in the DDR landscape included in this module are:
How Beacon DDR works
Search the trial and drug landscape by target, repair pathway and mechanism of action alongside 15 other search criteria including disease, line of therapy, biomarker, sponsor etc. to instantly extract the data points you need to conduct more complex analysis.